about
CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected IndividualsThe Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestryDuffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibilityApolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progressionIncreasing rates of obesity among HIV-infected persons during the HIV epidemicTreatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral loadThe major genetic determinants of HIV-1 control affect HLA class I peptide presentation.Health care transmission of a newly emergent adenovirus serotype in health care personnel at a military hospital in Texas, 2007.A comparison of HAART outcomes between the US military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS)Combining epidemiologic and biostatistical tools to enhance variable selection in HIV cohort analyses.HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 allelesRole of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy.The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.The continuum of HIV care in a Veterans' Affairs clinic.Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals.Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDSOutcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History StudyAre HIV-positive persons progressing faster after diagnosis over the epidemic?Outcomes after virologic failure of first-line ART in South AfricaSystematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutationsGender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity.Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experienceLong-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapyConcurrent use of traditional medicine and ART: Perspectives of patients, providers and traditional healers in Durban, South AfricaAnal cancers among HIV-infected persons: HAART is not slowing rising incidenceEffect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.Risk factors for AIDS-defining illnesses among a population of poorly adherent people living with HIV/AIDS in Atlanta, Georgia.Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.Spontaneous virologic suppression in HIV controllers is independent of delayed-type hypersensitivity test responsiveness.The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United StatesOral microbiome in HIV-associated periodontitis.Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States.Novel Predictors of Poor Retention Following a Down-Referral from a Hospital-Based Antiretroviral Therapy Program in South Africa.Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineDifferences in expression of gut-homing receptors on CD4+ T cells in black and white HIV-negative men who have sex with menCCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals
P50
Q19028101-C78F191A-868D-495E-8752-A65416AFFD9AQ24628840-60B76CCD-AA96-437A-9979-CC4C9AE71864Q24657233-2DE77F91-2118-4C55-B70D-39C78970E93FQ28284354-2AA81796-4EBF-4473-95E2-7FC0BBA8DFDFQ28473706-52942B31-209A-42C5-8964-FDB93C025D0DQ28476227-82FA1021-EA63-4F04-846C-176B9F22DB92Q29417018-CB566722-8BC7-4B0E-9266-F6E61324FB2CQ30227475-0918A6CB-EDEC-4AD7-8F8F-684CAA4C58D3Q30486127-B6EC8EDC-76D7-4EFD-9B72-56F79EAF436EQ31149210-DF5781E3-365D-44C6-B1E2-EF4F77513635Q33382373-F0007FD8-FA4E-4C18-B814-71AE95D06697Q33383193-286942C3-F737-4182-99B0-39A8202D903AQ33525046-F3207C02-55D3-4D4E-9A6F-79BB94CEAE60Q33566584-0AD7A37B-B9BE-4510-BE57-950E935344E6Q33647567-8B36B57D-6F4A-4CC7-8932-AF2893997DB7Q33699077-EE410FD4-86BA-4856-AA5D-9C1D8DC04090Q33916321-6E606335-B53A-4634-B172-F2FD5E22B643Q33951598-8BCFFA8E-725E-401F-B538-AA8349610CC8Q33984169-EA8AD5C7-F264-42EB-AA1C-DA7E6A983ECBQ33985234-3709DF4D-58CC-4430-876D-B74A2DD41271Q34331628-E8FC378A-B869-4CE0-9AAD-9B0DBE1D60E8Q34345205-6BB79EEB-BCAE-4E4E-A0A1-0CEC8DF310FAQ34427442-A0235BA8-CCFA-432A-B981-59510F230CBAQ34539475-59483013-6AC5-4DBA-A144-5250E703B2A2Q34569335-447754F9-E232-49AA-9372-0DEE90C2A34AQ34635757-2BA837E7-3E65-4C8A-A7FB-CBAC6BDF6C9DQ34674264-0F2DC8FE-8108-482E-8496-886C77E2F269Q35093196-978AD976-CEC0-4B6B-8AA6-42A824DC7F00Q35404442-6A7F1956-DF5E-4502-895F-AB7591A0A01EQ35449682-07D40B5E-F040-4039-917F-FC81C507801FQ35812127-93E11AA1-2A59-4DF5-AB4B-1ED8B57C527AQ35959321-3F40BFEE-A3C9-4BC4-821A-279C363DFC89Q35974433-431DB156-3E96-4095-82D8-581DA30E506BQ36318106-847FC646-8F5E-4F94-A7BE-159048FCBD8DQ36494658-A8029E3A-C1C3-4178-9A62-B9F0175297E2Q36756256-2A9D745D-53EF-4A35-BA97-F83329A2EB88Q36852619-C7B59154-39A7-425B-AFDB-A8013BCA5657Q36852626-46017CE3-1D81-4145-A727-A6659A122DAEQ36853156-4AA23524-9875-4175-A877-E81AB721DD4AQ37072697-F16F8846-FDB3-4129-895D-6703F8F99B2C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vincent C Marconi
@ast
Vincent C Marconi
@en
Vincent C Marconi
@es
Vincent C Marconi
@nl
Vincent C Marconi
@sl
type
label
Vincent C Marconi
@ast
Vincent C Marconi
@en
Vincent C Marconi
@es
Vincent C Marconi
@nl
Vincent C Marconi
@sl
prefLabel
Vincent C Marconi
@ast
Vincent C Marconi
@en
Vincent C Marconi
@es
Vincent C Marconi
@nl
Vincent C Marconi
@sl
P1053
N-3210-2014
P106
P21
P31
P3829
P496
0000-0001-8409-4689